Rockefeller Capital Management’s Corcept Therapeutics CORT Stock Holding History

Rockefeller Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.7M	Sell	123,388 -109	-0.1%	-$6.58K	0.02%	703
2026 Q1	$4.98M	Buy	123,497 +57,700	+88%	+$2.16M	0.01%	917
2025 Q4	$2.29M	Buy	65,797 +53,574	+438%	+$4.21M	﹤0.01%	1191
2025 Q3	$1.02M	Buy	+12,223	New	+$885K	﹤0.01%	1421
2023 Q1	–	Sell	-38	Closed	–	–	2348
2022 Q4	$0	Hold	38	–	–	﹤0.01%	3892
2022 Q3	$0	Sell	38 -193	-84%	-$5.17K	﹤0.01%	3942
2022 Q2	$5K	Buy	+231	New	+$5.03K	﹤0.01%	3431
2021 Q1	–	Sell	-5	Closed	–	–	3263
2020 Q4	$0	Buy	+5	New	+$105	﹤0.01%	2870

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rockefeller Capital Management's CORT Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Corcept Therapeutics (CORT) stake by 0.09% in Q2 2026, selling an estimated $6.58K and leaving 123,388 shares worth $10.7M. The position accounts for 0.02% of the portfolio, ranked #703.

Rockefeller Capital Management first reported a position in CORT in Q4 2020 and has held it in 8 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Rockefeller Capital Management held 123,388 shares of Corcept Therapeutics worth $10.7M as of Q2 2026.
Rockefeller Capital Management sold 109 Corcept Therapeutics shares in Q2 2026, an estimated $6.58K.
Corcept Therapeutics made up 0.02% of Rockefeller Capital Management's portfolio in Q2 2026, its #703 holding.
Rockefeller Capital Management first reported a position in Corcept Therapeutics in Q4 2020 and has held it in 8 quarters since.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.